[HTML][HTML] Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality

…, MA Senin, F Escalante, JE de la Puerta… - Blood cancer …, 2020 - nature.com
There is limited information on the characteristics, prognostic factors, and outcomes of patients
with multiple myeloma (MM) hospitalized with COVID-19. This retrospective case series …

Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development

…, J de la Rubia, JE de la Puerta… - Blood, The Journal …, 2021 - ashpublications.org
Although light-chain amyloidosis (AL) and multiple myeloma (MM) are characterized by
tumor plasma cell (PC) expansion in bone marrow (BM), their clinical presentation differs. …

Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis

…, A Pérez-Montaña, J de la Rubia, JE de la Puerta… - Leukemia, 2019 - nature.com
Early diagnosis and risk stratification are key to improve outcomes in light-chain (AL)
amyloidosis. Here we used multidimensional-flow-cytometry (MFC) to characterize bone marrow (…

[HTML][HTML] Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis

…, S Barrio, J Enrique de la Puerta… - Leukemia, 2021 - nature.com
Sequence-based analysis has come to play an integral role in many hematological
malignancies [1], but disorders such as systemic light-chain (AL) amyloidosis remain poorly …

Centrando al hospital en el cliente mediante el programa QFD.

JE de la Puerta Rueda - Qualitas hodie: Excelencia, desarrollo …, 1997 - dialnet.unirioja.es
Resumen El Hospital de Zumárraga pretende orientar su organizacion hacia el cliente
rediseñando los procesos asistenciales según sus especificaciones, para mejorar la …

[HTML][HTML] Longitudinal immunogenomic profiling of tumor and immune cells for minimally-invasive monitoring of smoldering multiple myeloma (SMM): the Immunocell …

…, R Loos, A Garcia-Guiñon, M Sirvent, JE de la Puerta… - Blood, 2020 - Elsevier
Background: Although great strides were made in the management of MM, our best chances
to eradicate this malignancy may lie in preventing its progression.Most current models to …

OAB-035: Minimally invasive profiling of tumor and immune cells to stratify risk in smoldering multiple myeloma (SMM): the iMMunocell study

…, T Jelinek, J Bargay, E Ocio, JE De La Puerta… - … Myeloma and Leukemia, 2021 - Elsevier
Background The 2/20/20 model to predict risk of transformation in SMM is established at
diagnosis and not periodically re-evaluated, mainly because plasma cell (PC) quantification …

[HTML][HTML] Multidimensional Immunophenotyping Identifies Hallmarks of Systemic Light-Chain Amyloidosis (AL) and Maps the Disease in the Crossroad between MGUS …

…, I Krsnik, A Pérez, J De La Rubia, JE de la Puerta… - Blood, 2018 - Elsevier
Background: Since survival in AL mainly depends on the extent of organ involvement of
patients at presentation, early diagnosis and risk stratification are key to improve patients' …

[PDF][PDF] Capitalismo y subjetividad.¿ Qué sujeto, qué vínculo y qué libertad?

JEE López - Psicoperspectivas, 2009 - redalyc.org
El capitalismo funciona articulado con un discurso sobre la libertad de elección y la autonomía
individual que, finalmente, nos hace menos libres y más incapaces de transformar lo que …

Multiple Myeloma and SARS-CoV-2 Infection: Clinical Characteristics and Prognostic Factors of Inpatient Mortality (preprint)

…, CF de Larrea, MA Senin, F Escalante, JE de la Puerta… - 2020 - pesquisa.bvsalud.org
There is limited information on the characteristics, pre-admission prognostic factors, and
outcomes of patients with multiple myeloma (MM) hospitalized with coronavirus disease 2019 (…